Cancer biotech TetraLogic sets terms for $90 million IPO


Shutterstock photo

TetraLogic Pharmaceuticals, which is developing small molecule therapeutics for the treatment of cancer, announced terms for its IPO on Wednesday. The Malvern, PA-based company plans to raise $90 million by offering 6.4 million shares at a price range of $13 to $15. At the midpoint of the proposed range, TetraLogic Pharmaceuticals would command a market value of $270 million.

TetraLogic Pharmaceuticals, which was founded in 2001, plans to list on the NASDAQ under the symbol TLOG. The company initially filed confidentially on September 16, 2013. Oppenheimer & Co., Guggenheim Securities and Needham & Co. are the joint bookrunners on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines , IPOs

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by